
FDA To Review Safety Of Abortion Pill After Junk Science Report Paved The Way
HuffPost
Republicans have been laying the groundwork to undermine the safety of mifepristone for months, despite the drug's proven safety record.
Republican Sen. Josh Hawley’s quest to legitimize a junk science report undermining the safety of a widely used abortion pill was fully realized this week.
Food and Drug Administration Commissioner Martin Makary confirmed in a Monday letter to the Missouri senator that the agency will conduct a safety review of the abortion pill mifepristone. Makary’s letter is in response to an April request from Hawley for the department to review mifepristone following a new report published by the Ethics and Public Policy Center, an anti-abortion conservative think tank and advisory board member of Project 2025.
“As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of early pregnancy,” Makary wrote in his letter. “As the Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone and working with the professional career scientists at the Agency who review this data.”
The FDA and the Department of Health and Human Services did not immediately respond to HuffPost’s request for comment.
Although Makary does not mention the EPPC report, Hawley’s entire argument for reviewing mifepristone relies on the junk science paper. The EPPC report claims it’s the “largest-known study of the abortion pill” and that nearly 11% of women “experience sepsis, infection, hemorrhaging, or another serious adverse event within 45 days following a mifepristone abortion.” But data scientists voiced serious concerns about the validity of the report, pointing out that it’s not peer-reviewed and the report’s recommendations do not line up with the data they analyzed.













